Back to top
more

InspireMD (NSPR)

(Real Time Quote from BATS)

$2.77 USD

2.77
38,105

+0.08 (2.97%)

Updated Aug 4, 2025 10:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

InspireMD Launches CGuard Prime Carotid Stent System in the U.S.

by Zacks Equity Research

NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.

Zacks Equity Research

InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

InspireMD (NSPR) delivered earnings and revenue surprises of -29.41% and 9.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of -8.11% and 4.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

IQVIA (IQV) delivered earnings and revenue surprises of 2.66% and 1.55%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

InspireMD, Inc. (NSPR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

InspireMD (NSPR) delivered earnings and revenue surprises of 5% and 6.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nuwellis, Inc. (NUWE) Reports Q4 Loss, Lags Revenue Estimates (Revised)

by Zacks Equity Research

Nuwellis (NUWE) delivered earnings and revenue surprises of -51.16% and -7.12%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nuwellis, Inc. (NUWE) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nuwellis (NUWE) delivered earnings and revenue surprises of 46.51% and 7.12%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Delcath Systems, Inc. (DCTH) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Delcath Systems (DCTH) delivered earnings and revenue surprises of 150% and 33.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sight Sciences (SGHT) delivered earnings and revenue surprises of -15% and 0.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 66.67% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study

by Zacks Equity Research

InspireMD announces the first patient enrolment in the CGUARDIANS II clinical trial.

Zacks Equity Research

InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

InspireMD (NSPR) delivered earnings and revenue surprises of 20% and 4.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sight Sciences (SGHT) delivered earnings and revenue surprises of 4.35% and 1.23%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Si-Bone (SIBN): Can Its 6.9% Jump Turn into More Strength?

by Zacks Equity Research

Si-Bone (SIBN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

ClearPoint Neuro (CLPT) Soars 6.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

ClearPoint Neuro (CLPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent

by Zacks Equity Research

NSPR gains premarket approval for its CGuard Prime carotid stent system for use in United States for treating carotid artery stenosis.

Zacks Equity Research

NSPR Stock Declines Despite PMA Application Submission for CGuard

by Zacks Equity Research

InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.

Zacks Equity Research

InspireMD, Inc. (NSPR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

InspireMD (NSPR) delivered earnings and revenue surprises of -15.79% and 0.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Shockwave Medical (SWAV) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 38.46% and 5.66%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS

by Zacks Equity Research

InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.

Zacks Equity Research

Down -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a Turnaround

by Zacks Equity Research

InspireMD, Inc. (NSPR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.29% and 5.31%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Zacks.com featured highlights include: Civeo, InspireMD, Westport Fuel Systems, Genesco and Radware

by Zacks Equity Research

Zacks.com featured highlights include: Civeo, InspireMD, Westport Fuel Systems, Genesco and Radware